Back to search

Belgium· BE-AMP-SAM538186-00

Oncaspar 750 U/ml

A pegaspargase product containing pegaspargase, registered in Belgium by Les Laboratoires Servier. The same ATC class is registered in 15 of our 19 countries.

ATC L01XX24

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedOncaspar 750 U/mlATCL01XX24REGISTER NO.BE-AMP-SAM538186-00PACKS LISTED2CHECKEDSeptember 26, 2026

Where it is registered

Pegaspargase is registered in 15 of 19 countries.

Countries holding a registration under ATC L01XX24 (pegaspargase), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 9 of them publish a price we can compare per daily dose

Pegaspargase · ATC L01XX24

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Pegaspargase
Manufacturer
Les Laboratoires Servier
Country
Belgium (BE)
ATC code
L01XX24
ATC class
Pegaspargase
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    7724255
  • be_apb
    3789708

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

441 interactions on record for pegaspargase.

Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Pegaspargase · interactions on record

441 records

  • 30 severe
  • 411 moderate

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • ClotrimazoleA01AB18moderate
  • Chenodeoxycholic acidA05AA01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/bf2eef56-bbf9-4c7c-b33a-9d3050ce76f7
GET /v1/drugs/bf2eef56-bbf9-4c7c-b33a-9d3050ce76f7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Powder for solution for injection/infusion",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Oncaspar 750 U/ml",
  "name_fr": "Oncaspar 750 U/ml",
  "name_nl": "Oncaspar 750 U/ml",
  "amp_code": "SAM538186-00",
  "strengths": [
    "750.0000"
  ],
  "pack_count": 1,
  "substances": [
    "Pegaspargase",
    "Disodium Hydrogen Phosphate Heptahydrate",
    "Sodium Chloride",
    "Sodium Dihydrogen Phosphate Monohydrate",
    "Sodium Hydroxide",
    "Sucrose"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Pegaspargase",
  "authorisation_numbers": [
    "EU/1/15/1070/002"
  ]
}

See everything about pegaspargase.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.